[Two cases of invasive pulmonary aspergillosis in non-immunocompromised hosts].
Invasive pulmonary aspergillosis generally occurs in immunocompromised hosts such as patients with leukemia, and other malignancies, who are receiving anti-cancer chemotherapy. In this report, two non-immunocompromised patients who developed invasive pulmonary aspergillosis are presented. Case 1: A 63-year-old man complained of productive cough and fever. He received antibiotic therapy from his personal physician. This symptoms did not respond, however, and dyspnea developed. He was then transferred to our hospital, about one month after the onset. The chest X-ray showed a meniscus shadow suggesting an aspergilloma in the right upper lung field and an infiltrative shadow in the remaining right lung field. Case 2: A 78-year-old man was admitted because of dyspnea, productive cough and appetite loss over the previous three months. The chest X-ray showed a meniscus shadow in the left upper field, an infiltrative shadow in the left lower field and a right pleural effusion sign was also observed. Both cases were diagnosed as having aspergillosis, early in their illness, by the detection of aspergillus antigen in their sera and histopathological and cultural studies of specimens obtained by TBLB. Both improved with intravenous amphotericin B (30 mg/day) and intravenous ulinastatin (200000 IU/day) administration. On the examinations conducted during hospitalization, there was no evidence of any immunosuppressive diseases or immunoincompetent conditions such as leukemia, and other malignancies human immunodeficiency virus infection, diabetes or alcoholism.
Sugimura
S
S
Department of Medicine, Kawasaki Medical School, Japan.
Yoshida
K
K
Oba
H
H
Hashiguchi
K
K
Nakajima
M
M
Moriya
O
O
Okimoto
N
N
Niki
Y
Y
Soejima
R
R
D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage; D001228:Aspergillosis / Q000188:drug therapy / Q000209:etiology*; D004359:Drug Therapy, Combination; D006023:Glycoproteins / Q000008:administration & dosage; D006801:Humans; D007121:Immunocompetence; D008172:Lung Diseases, Fungal / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D008875:Middle Aged
D006023:Glycoproteins; D000666:Amphotericin B; C028665:urinastatin